['cystic fibrosis']
['tez/iva', 'iva', 'placebo', 'placebo']

        Key Inclusion Criteria:

          -  Homozygous for F508del or heterozygous for F508del and an RF mutation (as defined in
             the protocol).

          -  Participants with ppFEV1 of ≥70 percentage points adjusted for age, sex, height.

          -  Participants with a screening LCI2.5 result ≥7.5.

          -  Participants who are able to swallow tablets.

        Key Exclusion Criteria:

          -  Clinically significant cirrhosis with or without portal hypertension.

          -  Colonization with organisms associated with a more rapid decline in pulmonary status.

          -  Solid organ or hematological transplantation.

        Other protocol defined Inclusion/Exclusion criteria may apply.
      